FAPα-Cleavable Linker for Localized Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic drugs often face limitations due to immune-related toxicities and dose-limiting factors, particularly when inducing innate immune responses, as systemic innate immune activation restricts the maximum tolerated dose, preventing therapeutic efficacy.
Innovation Solution
Development of serum half-life extended drug conjugates with a linker that is selectively cleaved by fibroblast activating protein alpha (FAPα), allowing local release of the therapeutic moiety in the tumor microenvironment without systemic toxicity, using a half-life extension moiety and a cleavable linker that is specifically cleaved by FAPα present in tumor environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemic delivery of therapeutic drugs is used, then the drug can reach therapeutic levels in subjects, but immune-related toxicities and dose-limiting factors prevent practical efficacy
Solution Approach 1:
The patent applies local quality by designing a conjugate system that accumulates specifically in the tumor microenvironment through FAPα expression, releasing the therapeutic moiety locally rather than systemically. This creates a localized therapeutic effect that avoids systemic immune activation while maintaining efficacy at the tumor site.
Solution Approach 2:
The patent uses an intermediary approach by introducing a FAPα-cleavable linker as a mediator between the half-life extension moiety and the therapeutic moiety. This linker remains stable in circulation but is specifically cleaved by FAPα in the tumor microenvironment, enabling controlled local release of the therapeutic agent without systemic exposure.
2Quantity of substance
If maximum tolerated dose is increased to reach therapeutic level, then therapeutic efficacy is achieved, but systemic toxicity increases
Solution Approach 1:
The patent segments the therapeutic conjugate into distinct functional components: a half-life extension moiety, a FAPα-cleavable linker, and a therapeutic moiety. This segmentation allows the system to circulate as a stable conjugate for extended periods while enabling controlled release of the therapeutic agent specifically at the tumor site through FAPα-mediated cleavage, thereby achieving high local concentrations without proportional systemic toxicity.
3Quantity of substance
If a cell-binding moiety is used to target tumor cells, then specific delivery is achieved, but the conjugate structure becomes more complex
Solution Approach 1:
The patent applies self-service by utilizing the natural FAPα expression pattern in the tumor microenvironment as the targeting mechanism. Instead of adding an external cell-binding moiety, the system leverages the tumor's own FAPα proteins to mediate conjugate accumulation and release. The FAPα-cleavable linker automatically responds to the local FAPα presence, enabling the conjugate to self-target and self-release without requiring additional targeting components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables local delivery of a therapeutically effective amount of the drug to the tumor microenvironment, increasing the maximum tolerated dose and reducing systemic toxicity, thereby enhancing therapeutic efficacy while maintaining a superior therapeutic index.
Implementation Method 1
a linker including an FAPα substrate that can be selectively cleaved by fibroblast activating protein alpha (FAPα) to release the therapeutic moiety at the site of cleavage
Implementation Method 2
therapeutic conjugate comprising a therapeutic moiety linked through a FAPα-cleavable linker to a half-life extension moiety, wherein the circulating serum half-life of the therapeutic conjugate in vivo is at least 48 hours
Data Source
AI summary
Disclosed herein are therapeutic conjugates having an extended circulating serum half-life. The therapeutic conjugates comprise a therapeutic moiety linked to a half-life extension moiety via a fibroblast activation protein, alpha (FAPα)-cleavable linker. Methods of using the therapeutic conjugates are also provided.